Can MRGPRX2 inhibition prevent migraine? Evommune’s EVO756 enters Phase 2b study
Evommune begins a Phase 2b EVO756 migraine trial after a urticaria setback, testing whether MRGPRX2 inhibition can deliver preventive benefit.
Pharma & Biotech
Pharma & Biotech
Can Evommune turn EVO756 into a cross-indication inflammatory franchise with migraine next?
Evommune is taking EVO756 into migraine prophylaxis. Read why MRGPRX2 inhibition could matter, and what risks still cloud the story.
Pharma & Biotech
What Arcus Biosciences’ STAR-221 failure reveals about TIGIT fatigue in immunotherapy
Arcus Biosciences, Inc. has terminated its global Phase 3 STAR-221 study evaluating domvanalimab, an investigational anti-TIGIT antibody, in combination with zimberelimab and chemotherapy for advanced upper gastrointestinal cancers. The discontinuation, announced in partnership with Gilead Sciences, Inc., followed a pre-specified interim overall survival analysis that found no benefit compared to the nivolumab-based control arm. Arcus